Standardized Approach Needed to Evaluate Neuropathic Cancer Pain
A standardized approach is vital for the assessment of neuropathic cancer pain in order to improve treatment results and future clinical/pre-clinical studies.
Diagnosis & Disease Information
Peripheral Neuropathy Frequent for Childhood Cancer Survivors
Long-term neurotoxicity was more frequently seen with cisplatin than with vinca alkaloids, data indicates.
Exercise Reduces Severity of Chemotherapy-Induced Peripheral Neuropathy
For this study, researchers sought to determine the effect exercise would have on severity of symptoms for patients who develop CIPN after taxane, platinum, or vinca alkaloid based chemotherapy.
Research Shows Vitamin B3 Reduces Pain From Chemotherapy-Induced Peripheral Neuropathy
Nicotinamide riboside, a type of B3 vitamin, was shown to prevent chemotherapy-induced peripheral neuropathy in an animal-model study.
Managing Treatment-related Peripheral Neuropathy in Patients with Multiple Myeloma
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews clinical symptoms, diagnosis, and risk factors of peripheral neuropathy, particularly dealing with the incidence, mechanisms, and management of TiPN and BiPN.
Tango Dancing Improves Balance and Fall Risk in Cancer Patients With Peripheral Neuropathy
Balanced is improved and fall risk is reduced among cancer patients with peripheral neuropathy who participated in Argentine tango dancing as a form of therapy.
Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer
Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.
Neurofeedback Training Enables Cancer Survivors to Control Chemotherapy-Induced Peripheral Neuropathy
Chronic pain was decreased and quality of life was increased through neurofeedback.
Rare gene variants associated with side effects from paclitaxel
Researchers have identified the first genetic marker associated with severe neurologic toxicity from paclitaxel.
- Loading...
Loading...
Next post in Web Exclusives
Loading... 
Loading...